Amicus Therapeutics, Inc. (FOLD) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Biotechnologie Branche. Der Hauptsitz des Unternehmens ist in Philadelphia, PA, United States. Der aktuelle CEO ist Bradley L. Campbell.
FOLD hat IPO-Datum 2007-05-31, 499 Vollzeitbeschäftigte, gelistet an der NASDAQ Global Market, eine Marktkapitalisierung von $4.54B.
Amicus Therapeutics, Inc. is a biotechnology company headquartered in Philadelphia that specializes in discovering, developing, and commercializing medicines for rare genetic diseases. The company's lead commercial product is Galafold, an oral precision medicine approved for treating adults with Fabry disease who carry amenable galactosidase alpha gene variants. Its pipeline includes AT-GAA for Pompe disease, AT-GTX-502, a gene therapy in Phase 1/2 development for CLN3 disease, and a gene therapy program targeting CDKL5 deficiency. Amicus maintains strategic collaborations with major research institutions including Nationwide Children's Hospital, University of Pennsylvania, and GlaxoSmithKline to advance its development programs. Founded in 2002, the company is focused on addressing significant unmet medical needs in the rare disease community.
